“…Based on the type of omics evidence they provide, we classified the studies as guiding (genomics studies), corroborating (epigenomics and transcriptomics studies) and additional (metabolomics and microbiome) studies. For the genomics data, we compiled a list of TD candidate genes from studies of rare genetic variants/events—(i) eight chromosomal rearrangements studies [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ] (the main list includes 15 genes and the extended list consists of 23 genes), (ii) fifteen single-nucleotide variation (SNV) studies [ 27 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ] (the main list includes 134 genes and the extended list consists of 846 genes), and (iii) eleven copy number variations (CNV) studies [ 37 , 44 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ] (the main list includes 52 genes, and the extended list consists of 956 genes)—and studies of common genetic variants (of single-nucleotide polymorphisms or SNPs), i.e., genome-wide association studies (GWASs). The GWAS-derived genes include the results from our own unpublished analyses of the summary statistics data from the TD GWAS by Yu et al [ 55 ], i.e., 113 genes from the MAGMA analysis, 224 genes from the FUMA analysis, and 143 genes from the TWAS analysis.…”